Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#407 of 449

Jason Kolbert

D. Boral Capital · Equity Research Analyst
ProvisionalRating since 2024No new ratings since Aug 2025

Analyst rating accuracy & track record

Jason Kolbert is an equity research analyst at D. Boral Capital. Quantellect has scored 245 of their stock calls across 36 companies. Their picks beat their sector 22% of the time over the next 12 months, and their price targets were reached 12% of the time within a year.

Win % vs sector
22%
PT Hit % (12mo)
12%
Avg sector-excess
−23.4%
Scored calls
245
Tickers
36
Tier
Provisional

Track record

Quantellect has scored 245 of Jason Kolbert's stock calls across 36 companies, dating back to 2024. Their rated stocks beat their own sector 22% of the time over the next 12 months. On a typical call, a Kolbert pick returned −23.4% more than its sector over the following year.

Of the scored calls, 245 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
XAIRBeyond Air Inc
Buy$11.00Aug 2025+96.0%Miss
CLGNCollplant Biotechnologies Ltd
Buy$12.00Aug 2025−114.2%Miss
CTSOCytosorbents Crp
Buy$10.00Aug 2025−90.6%Miss
ANIXAnixa Biosciences Inc
Buy$10.00Aug 2025−2.4%Miss
ENLVEnlivex Therapeutics Ltd
Buy$13.00Aug 2025+19.0%Miss
CRVOCervoMed Inc.
Buy$31.00Aug 2025−97.2%Miss
ARTLArtelo Biosciences Inc
Buy$18.00Aug 2025−123.3%Miss
RVPHReviva Pharmaceuticals Holdings Inc.
Buy$3.00Aug 2025−121.4%Miss
CRVOCervoMed Inc.
Buy$31.00Aug 2025−97.2%Miss
CRVOCervoMed Inc.
Buy$31.00Aug 2025−97.2%Miss
NRSNNeurosense Therapeutics Ltd
Buy$14.00Aug 2025−90.0%Miss
CODXCo-Diagnostics, Inc. Common Stock
Buy$10.00Aug 2025−110.6%Miss
OMEROmeros Corporation
Buy$36.00Aug 2025+286.4%Miss
VNRXVolitionrx Ltd
Buy$5.00Aug 2025−120.9%Miss
QNCXQuince Therapeutics, Inc.
Buy$4.00Aug 2025+79.8%Hit
XAIRBeyond Air Inc
Buy$11.00Aug 2025+170.9%Miss
MDCXMedicus Pharma Ltd. Common Stock
Buy$27.00Aug 2025−103.8%Miss
NNOXNano X Imaging Ltd
Buy$8.00Aug 2025−105.4%Miss
AVXLAnavex Life Sciences Corp
Buy$46.00Aug 2025−95.0%Miss
COYACoya Therapeutics, Inc. Common Stock
Buy$18.00Aug 2025−45.2%Miss
CMPXCompass Therapeutics Inc.
Buy$32.00Aug 2025−51.6%Miss
ESLAEstrella Immunopharma Inc.
Buy$16.00Aug 2025−41.0%Miss
CRVOCervoMed Inc.
Buy$15.00Aug 2025−96.9%Miss
IMUXImmunic Inc
Buy$10.00Aug 2025+35.1%Miss
CTSOCytosorbents Crp
Buy$10.00Aug 2025−100.8%Miss
CNTXContext Therapeutics Inc
Buy$9.00Aug 2025−61.7%Miss
GOVXGeoVax Labs Inc
Buy$9.00Aug 2025−124.4%Miss
URGNUroGen Pharma Ltd
Buy$25.00Aug 2025+135.7%Hit
BMEABiomea Fusion Inc
Buy$16.00Aug 2025−52.4%Miss
ARTLArtelo Biosciences Inc
Buy$18.00Aug 2025−126.4%Miss
ANIXAnixa Biosciences Inc
Buy$10.00Aug 2025−17.4%Miss
URGNUroGen Pharma Ltd
Buy$25.00Aug 2025+104.6%Hit
AVXLAnavex Life Sciences Corp
Buy$46.00Aug 2025−95.0%Miss
ARTLArtelo Biosciences Inc
Buy$18.00Aug 2025−121.2%Miss
CEROCERo Therapeutics Holdings, Inc. Common Stock
Buy$30.00Aug 2025−123.8%Miss
FBLGFibroBiologics, Inc. Common Stock
Buy$16.00Aug 2025−116.5%Miss
LUNGPulmonx Corp
Buy$16.00Jul 2025−24.3%Miss
ENLVEnlivex Therapeutics Ltd
Buy$13.00Jul 2025+20.6%Miss
GOVXGeoVax Labs Inc
Buy$9.00Jul 2025−121.8%Miss
FBLGFibroBiologics, Inc. Common Stock
Buy$16.00Jul 2025−120.3%Miss
CRVOCervoMed Inc.
Buy$10.00Jul 2025−95.6%Hit
CRVOCervoMed Inc.
Buy$10.00Jul 2025−91.7%Hit
OMEROmeros Corporation
Buy$36.00Jul 2025+150.9%Miss
MNOVMediciNova Inc
Buy$9.00Jul 2025−30.3%Miss
COYACoya Therapeutics, Inc. Common Stock
Buy$18.00Jul 2025−56.9%Miss
ENLVEnlivex Therapeutics Ltd
Buy$13.00Jul 2025+273.4%Miss
BMEABiomea Fusion Inc
Buy$16.00Jul 2025−48.5%Miss
CTSOCytosorbents Crp
Buy$10.00Jul 2025−82.2%Miss
XAIRBeyond Air Inc
Buy$11.00Jul 2025+47.4%Miss
XAIRBeyond Air Inc
Buy$11.00Jul 2025+47.4%Miss
Prev1
Go to

Jason Kolbert: analyst track record FAQ

Is Jason Kolbert a good stock analyst?

Yes, by track record. Jason Kolbert ranks number 407 of 449 of the analysts Quantellect scores, with a Q Score of 0 out of 100. Past results do not guarantee future ones.

What is Jason Kolbert's win rate?

Jason Kolbert's win rate is 22%. Across 245 scored calls, their rated stocks beat their sector 22% of the time over the next 12 months. On a typical call they returned −23.4% more than the sector.

What stocks and sectors does Jason Kolbert cover?

Jason Kolbert covers 36 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Jason Kolbert's price targets accurate?

Jason Kolbert's price targets are reached within 12 months 12% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Jason Kolbert's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Jason Kolbert rank among Wall Street analysts?

Jason Kolbert ranks number 407 of 449 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.